Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Product Name : ET-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company’s 1st-in-class gene therapy ET-101 has been engineered to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function.
Product Name : ET-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-ICON3
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : CincyTech
Deal Size : Undisclosed
Deal Type : Series A Financing
Details : Funding will support Investigational New Drug (IND) enabling studies for Eikonoklastes Therapeutics’ L-ICON3 immune conjugate platform.
Product Name : L-ICON3
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : L-ICON3
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : CincyTech
Deal Size : Undisclosed
Deal Type : Series A Financing